There is no damage that could affect the stock by the appearance, only upside. The next campaign for Pona is to move it to the front line. The more doctors and patients know about the drug, hear about the drug, will promote that effort. It is guarenteed that doctors and patients and investors do not have perfect knowledge of what drugs are out there. They need to be continually educated. HB had them in session yesterday. The more he does it the better, especially in the long term. In the short term, we get a little pop.
FYI, Cramer just mentioned Ariad again on cnbc.
